OBJECTIVES The goal of this study was to develop and validate a noninvasive imaging tool to visualize the in vivo behavior of high-density lipoprotein (HDL) by using positron emission tomography (PET), with an emphasis on its plaquetargeting abilities.
A therosclerosis is a systemic inflammatory disorder that underlies cardiovascular disease (1) . Lipid deposition and immune cell infiltration drive development of atherosclerotic plaque (2) , which can eventually rupture (3), potentially causing atherothrombosis and ensuing acute coronary events (4) .
High-density lipoprotein (HDL), a natural nanoparticle mainly composed of phospholipids, cholesterol and cholesteryl esters, and apolipoprotein A-I (apo A-I), is involved in the process of reverse cholesterol transport (5) . HDL and apo A-I have demonstrated atheroprotective properties (6) (7) (8) . The principal mechanism whereby HDL exerts this protective effect is generally ascribed to promoting cholesterol efflux from macrophages in plaques and transporting it to the liver for excretion, although other antiatherogenic properties have been reported (9) . Cholesterol efflux is mediated by several membrane receptors abundantly expressed on macrophages to which apo A-I and HDL bind (10, 11) .
The study of HDL can be modernized by the integration of noninvasive imaging. Capitalizing on its properties, our group pioneered the use of HDL magnetic resonance imaging (MRI) (12, 13) . However, to noninvasively study the pharmacokinetics, trafficking, and metabolism of HDL, a quantitative and highly sensitive modality is warranted. Recent advances in labeling technology now allow positron emission tomography (PET) radiotracer imaging at unprecedented high-sensitivity down to the picomolar range, at limitless tissue penetration, in a so-called "hot spot" fashion (14) . Tracing of HDL requires longlived radioisotopes because, upon intravenous administration, it circulates for extended periods of time. Recently, we have developed modular zirconium-89 ( 89 Zr)-labeling methods for lipid-based nanoparticles (15, 16) . The physical half-life of 89 Zr (78.4 h) makes it an ideal radiolabel for such long-circulating materials (15) and provides an opportunity to study the in vivo behavior of the HDL nanoparticles.
Through extensive studies involving a unique arrangement combining PET/ computed tomography (CT) and PET/MRI in murine, rabbit, and porcine atherosclerosis models, the present paper illustrates that 89 Zr labeling is a valuable tool to noninvasively assess the pharmacokinetics and distribution of the main components of HDL.
METHODS
A detailed description of the animal models and experimental procedures can be found in These particles were prepared in a manner identical to that of their radioactive counterparts but contained the dye DiR (Online Table 1 ) and nonradioactive Pérez-Medina et al.
PET Imaging of HDL in Atherosclerosis
A U G U S T 2 0 1 6 : 9 5 0 -6 1 Figure 1 .
Pérez-Medina et al. Intense signals from the kidneys were also observed at all time points for 89 Zr-PL-HDL. In both cases, bone radioactivity accumulation was also detected over the Abbreviations as in Figures 1 and 2 .
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A U G U S T 2 0 1 6 : 9 5 0 -6 1 accumulation in lesions ( Figure 6B ). Analysis according to NIRF imaging found increased accumulation of Cy5.5-HDL in atherosclerotic aortas.
A good correlation was found between total radiant efficiency and radioactivity concentration ( Figure 6C , Online Figure 8B ). Interestingly, the correlation between radioactivity concentration and Cy7-albumin NIRF intensity was weak (Online SUVs as high as 48 g/ml (1.0 %ID/g). These values were significantly higher than those measured for 89 Zr-AI-HDL in control animals and rabbits with atherosclerosis (Online Figure 9D) . PET-quantified SUVs were qualitatively similar to the values obtained after the day 5 scan by using ex vivo gamma counting (Online Figure 9D) . Interestingly, radioactivity accumulation in atherosclerotic aortas for 
-HDL (bottom). (C)
Comparison between NIRF intensity (total radiant efficiency, in mW/cm 2 ) and radioactivity concentration in aortas of rabbits with atherosclerosis and wild-type control animals at 5 days' post-administration of 89 Zr-AI-HDL and Cy5.5-HDL (top) and 89 Zr-PL-HDL and Cy5.5-HDL (bottom) (n ¼ 4 per group). *p < 0.05. Abbreviations as in Figures 1, 2, 3 , and 5.
89 Zr-AI-HDL Ox was significantly lower than for nonoxidized 89 Zr-AI-HDL (Online Figure 9E) . Figure 7A . Strong signals were observed in the kidneys, liver, and bone, as well as in the intestines.
High radioactivity accumulation in the femoral arteries could be clearly observed in vivo ( Figure 7B ).
Radioactivity concentration in these vessels was higher than in noninjured internal iliac arteries, which served as controls. Radioactivity distribution in selected organs determined according to gamma counting after the 48 h scan is shown in Figure 7C and mirrors the PET imaging observations. The increased signal in the femoral arteries was due to accumulation in lesions, as corroborated by ex vivo autoradiography analysis ( Figure 7D) .
DISCUSSION
In the present study, we developed and validated a noninvasive quantifiable PET imaging tool to study the in vivo behavior of HDL in multiple atherosclerosis models. Using nonradioactive fluorescent analogues of the 89 Zr-labeled nanoparticles, we found that both preferentially targeted macrophages in the atherosclerotic aortas of Apoe -/-mice, in line with our previous studies (17, 18) . This finding also suggests that the modifications were well tolerated and did not affect the ability of HDL to interact with plaque macrophages (19 Modification of apo A-I can affect its blood circulation time as reported for radioiodination (21) , which has frequently been used to study the pharmacokinetics and metabolism of the protein and of HDL (22) .
This labeling strategy is convenient and results in iodination of tyrosine residues as well as faster clearance than the unmodified protein (21), which is most likely due to rapid deiodination by deiodinases (23) .
Therefore, label stability and kinetics play an important role when designing an imaging tool. Importantly, using our approach, the radioactivity blood half-life of Pérez-Medina et al.
